Peel Hunt Reaffirms Buy Rating for Clinigen Group PLC (CLIN)
Clinigen Group PLC (LON:CLIN)‘s stock had its “buy” rating reissued by equities research analysts at Peel Hunt in a research note issued on Thursday. They currently have a GBX 1,200 ($15.58) price objective on the stock. Peel Hunt’s price target points to a potential upside of 13.96% from the company’s previous close.
Other equities research analysts have also recently issued research reports about the stock. Numis Securities Ltd reiterated a “buy” rating and set a GBX 951 ($12.35) target price on shares of Clinigen Group PLC in a research report on Monday, May 22nd. Stifel Nicolaus reiterated a “buy” rating and set a GBX 970 ($12.59) target price on shares of Clinigen Group PLC in a research report on Monday, May 22nd.
Clinigen Group PLC (LON CLIN) traded up 1.45% on Thursday, reaching GBX 1053.00. 269,195 shares of the company’s stock traded hands. Clinigen Group PLC has a 52-week low of GBX 627.50 and a 52-week high of GBX 1,053.00. The stock’s market capitalization is GBX 1.21 billion. The firm’s 50-day moving average is GBX 957.23 and its 200 day moving average is GBX 869.37.
In other Clinigen Group PLC news, insider John Bacon sold 200,000 shares of the firm’s stock in a transaction dated Wednesday, June 28th. The shares were sold at an average price of GBX 843 ($10.94), for a total value of £1,686,000 ($2,188,757.63). Also, former CEO Peter George sold 500,000 shares of the firm’s stock in a transaction dated Thursday, June 22nd. The shares were sold at an average price of GBX 875 ($11.36), for a total transaction of £4,375,000 ($5,679,605.35).
Clinigen Group PLC Company Profile
Receive News & Ratings for Clinigen Group PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group PLC and related companies with MarketBeat.com's FREE daily email newsletter.